Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia

Gene Therapy

Volumn 12, Issue 6, 2005, Pages 487-493

  Takada, J ^a   Ooboshi, H ^a   Ago, T ^a   Kitazono, T ^a   Yao, H ^a   Kadomatsu, K ^b   Muramatsu, T ^b   Ibayashi, S ^a   Iida, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenovirus; Apoptosis; Brain ischemia; Gene transfer; Midkine

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; MIDKINE; TRIPHENYLTETRAZOLIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN SLICE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC CODE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BETA-GALACTOSIDASE; BRAIN; BRAIN ISCHEMIA; CYTOKINES; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MALE; MODELS, ANIMAL; RATS; RATS, INBRED SHR;

ADENOVIRIDAE;

EID: 15944367385     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302434     Document Type: Article

References (39)

1. Tomomura M et al. A retinoic acid-responsive gene, MK, found in the teratocarcinoma system. Heterogeneity of the transcript and the nature of the translation product. J Biol Chem 1990; 265: 10765-10770.
2. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988; 151: 1312-1318.
3. Muramatsu H, Muramatsu T. Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem Biophys Res Commun 1991; 177: 652-658.
4. Muramatsu H et al. Midkine, a retinoic acid-inducible growth/ differentiation factor: immunochemical evidence for the function and distribution. Dev Biol 1993; 159: 392-402.
5. Kikuchi S et al. Midkine, a novel neurotrophic factor, promotes survival of mesencephalic neurons in culture. Neurosci Lett 1993; 160: 9-12.
6. Michikawa M et al. Retinoic acid responsive gene product, midkine, has neurotrophic functions for mouse spinal cord and dorsal root ganglion neurons in culture. J Neurosci Res 1993; 35 530-539.
7. Satoh J et al. Midkine that promotes survival of fetal human neurons is produced by fetal human astrocytes in culture. Brain Res Dev Brain Res 1993; 75: 201-205.
8. Unoki K et al. Rescue of photoreceptors from the damaging effects of constant light by midkine, a retinoic acid-responsive gene product. Invest Ophthalmol Vis Sci 1994; 35: 4063-4068.
9. Kojima S et al. Midkine enhances fibrinolytic activity of bovine endothelial cells. J Biol Chem 1995; 270: 9590-9596.
10. Yoshida Y et al. Midkine is present in the early stage of cerebral infarct. Brain Res Dev Brain Res 1995; 85: 25-30.
11. Yao H et al. DNA fragmentation in ischemic core and penumbra in focal cerebral ischemia in rats. Brain Res Mol Brain Res 2001; 91: 112-118.
12. Owada K et al. Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem 1999; 73: 2084-2092.
13. Yoshida Y et al. Intraventricular administration of the neurotrophic factor midkine ameliorates hippocampal delayed neuronal death following transient forebrain ischemia in gerbils. Brain Res 2001; 894: 46-55.
14. Heistad DD, Faraci FM. Gene therapy for cerebral vascular disease. Stroke 1996; 27: 1688-1693.
15. Ooboshi H et al. Adenovirus-mediated gene transfer in vivo to cerebral blood vessels and perivascular tissue. Circ Res 1995; 77: 7-13.
16. Betz AL, Yang GY, Davidson BL. Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J Cereb Blood Flow Metab 1995; 15 547-551.
17. Xu DG et al. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nat Med 1997; 3 997-1004.
18. Yang GY et al. Attenuation of ischemia-induced mouse brain injury by SAG, a redox-inducible antioxidant protein. J Cereb Blood Flow Metab 2001; 21: 722-733.
19. Zhang WR et al. Therapeutic time window of adenovirus-mediated GDNF gene transfer after transient middle cerebral artery occlusion in rat. Brain Res 2002; 947: 140-145.
20. Hayashi K et al. Gene therapy for preventing neuronal death using hepatocyte growth factor: in vivo gene transfer of HGF to subarachnoid space prevents delayed neuronal death in gerbil hippocampal CA1 neurons. Gene Therapy 2001; 8: 1167-1173.
21. Kumon Y et al. Transient increase in endogenous basic fibroblast growth factor in neurons of ischemic rat brains. Brain Res 1993; 605: 169-174.
22. Kokaia Z et al. Rapid alterations of BDNF protein levels in the rat brain after focal ischemia: evidence for increased synthesis and anterograde axonal transport. Exp Neurol 1998; 154 289-301.
23. Sugimori H, Speller H, Finklestein SP. Intravenous basic fibroblast growth factor produces a persistent reduction in infarct volume following permanent focal ischemia in rats. Neurosci Lett 2001; 300: 13-16.
24. Schäbitz WR et al. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke 2000; 31: 2212-2217.
25. Relton JK et al. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 1996; 138: 206-213.
26. Chang ML et al. Nicotinamide and ketamine reduce infarct volume and DNA fragmentation in rats after brain ischemia and reperfusion. Neurosci Lett 2002; 322: 137-140.
27. Linnik MD et al. Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke 1995; 26: 1670-1674; discussion 1675.
28. Yagi T et al. Rescue of ischemic brain injury by adenoviral gene transfer of glial cell line-derived neurotrophic factor after transient global ischemia in gerbils. Brain Res 2000; 885: 273-282.
29. Lawrence MS et al. Herpes simplex viral vectors expressing bcl-2 are neuroprotective when delivered after a stroke. J Cereb Blood Flow Metab 1997; 17: 740-744.
30. Padfield PJ, Elliott AC, Baldassare JJ. Adenovirus-mediated gene expression in isolated rat pancreatic acini and individual pancreatic acinar cells. Pflugers Arch 1998; 436: 782-787.
31. Tran QK et al. Midkine inhibits bradykinin-stimulated Ca(2+) signaling and nitric oxide production in endothelial cells. Biochem Biophys Res Commun 2000; 276: 830-836.
32. Takada T et al. Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem (Tokyo) 1997; 122: 453-458.
33. Shibata Y et al. Nuclear targeting by the growth factor midkine. Mol Cell Biol 2002; 22: 6788-6796.
34. Davidson BL et al. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993; 3: 219-223.
35. Ooboshi H et al. Augmented adenovirus-mediated gene transfer to atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997; 17: 1786-1792.
36. Ooboshi H et al. Adenovirus-mediated gene transfer to ischemic brain: ischemic flow threshold for transgene expression. Stroke 2001; 32: 1043-1047.
37. Yao H et al. Simplified model of krypton laser-induced thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats. Stroke 1996; 27: 333-336.
38. Tsutsui J et al. A new family of heparin-binding factors: strong conservation of midkine (MK) sequences between the human and the mouse. Biochem Biophys Res Commun 1991; 176: 792-797.
39. Takei Y et al. 5′-,3′-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine - its design and application for cancer therapy. J Biol Chem 2002; 277: 23800-23806.